BioMarin: Genzyme virus problem won

disqualify-sida.blogspot.com
Genzyme (NASDAQ: GENZ) found a virues strain and stopped production of two drugx atthe Allston, facility. The strain, Vesivirus 2117, apparentlty does not cause human infection but interrupts the growth of cellws that are used to make Aldurazyme — a treatment for MPS I, a rare and fataol disease caused by an enzymee deficiency — was last filled at the Genzyme facilituy in September 2008, according to BioMarin (NASDAQ: BMRN). The compangy has about 10 months of vialed inventory on it said, and uses a second fill finish A third supplier is expectex to be qualified later this BioMarin said. BioMarin makes the bulk materialp used in Aldurazyme at itsNovato facility.
The Food and Drug Administratio n hadinspected Genzyme’s plant in Septembet and October and reportedly was concerned about controlsa to protect against contamination.